International Journal on Science and Technology (IJSAT)

E-ISSN: 2229-7677 ● Website: www.ijsat.org ● Email: editor@ijsat.org

Therapeutic Potential of Vitex negundo for the Treatment of Polycystic Ovarian Disease (PCOD): A Review

Sonali. P[1], Leelambigai. D[2], Abarna. S[3], Dr. Ravishankar Rajendran[4]

[1]UG Scholar, Nandha Siddha Medical College and Hospital, Erode-52.
[2]Associate professor, Department of Sool Magalir Maruthuvam,
Nandha Siddha Medical College and Hospital, Erode-52.
[3]Assistant professor, Department of Sool Magalir Maruthuvam,
Nandha Siddha Medical College and Hospital, Erode-52.
[4]Bachelor of siddha medicine and surgery
Department of sool matrum magalir maruthuvam
Nandha siddha medical college and hospital

Abstract:

Polycystic ovarian disease (PCOD), synonymous in most literature with polycystic ovary syndrome (PCOS), is a frequent endocrine and metabolic disorder among women of reproductive age. It is marked by chronic anovulation, clinical or biochemical hyperandrogenism, and characteristic polycystic ovarian morphology. Standard treatments such as combined oral contraceptives, insulin sensitizers, and ovulation-inducing agents largely offer symptomatic relief and may be limited by adverse effects, contraindications, or poor compliance. In parallel, there is growing interest in herbal agents that can target multiple aspects of PCOD pathophysiology with a favorable safety profile. Vitex negundo L. (family Lamiaceae), known as Nirgundi, is widely used in Ayurveda and folk medicine for gynecological disorders, pain, inflammation, and menstrual irregularities. This review summarizes current information on PCOD pathophysiology and examines pharmacognostic details, phytochemistry, pharmacological actions, and available preclinical and clinical evidence regarding Vitex negundo, with specific focus on mechanisms relevant to PCOD, such as anti-inflammatory, antioxidant, metabolic and potential endocrine-modulating effects. Experimental studies in animal models of PCOD indicate beneficial effects on ovarian morphology, estrous cyclicity, oxidative stress, and metabolic parameters. Human data remain preliminary and often confounded by polyherbal formulations. There is a strong mechanistic rationale for Vitex negundo as an adjunct in PCOD management; however, well-designed randomized controlled trials with standardized extracts are required before routine clinical use can be recommended.

Keywords: Vitex negundo, Nirgundi, PCOD, PCOS, herbal medicine, insulin resistance, hyperandrogenism, ovarian cysts.

1. Introduction:

Polycystic ovarian disease is one of the most common endocrine disorders in women of reproductive age, with a prevalence ranging from 6 to 20% depending on diagnostic criteria and population studied [1,2]. It is a leading cause of chronic anovulation and subfertility and is strongly associated with insulin resistance, obesity, type 2 diabetes, dyslipidemia, and cardiovascular risk [3]. Clinical manifestations include menstrual irregularities, hirsutism, acne, obesity, and psychological disturbances that impair quality of life.Conventional treatment strategies are primarily symptom-directed and include lifestyle modification, combined oral contraceptives, insulin sensitizers such as metformin, ovulation-inducing agents (clomiphene citrate, letrozole, gonadotropins), and anti-androgens [3,4]. These therapies are often effective but can be associated with gastrointestinal complaints, weight changes, mood alterations, and contraindications in women seeking conception or having comorbidities.In recent years many patients have turned toward plant-based remedies, especially from traditional systems, as adjuncts or alternatives. Vitex species have attracted particular interest because of their long-standing use in gynecological conditions. Vitex agnus-castus has established evidence in premenstrual syndrome and mastalgia [5,6]. Vitex negundo, although more often described for its analgesic and anti-inflammatory properties, has been used traditionally for menstrual disorders and reproductive complaints [7,8]. This review provides an overview of PCOD pathophysiology, outlines the pharmacognostic and phytochemical features of Vitex negundo, and examines how its pharmacological profile may be relevant for PCOD management. Limited clinical evidence is discussed, and research gaps are identified.

Polycystic Ovarian Disease: Definition and Pathophysiology

Diagnostic criteria

PCOD/PCOS is diagnosed primarily using the Rotterdam criteria (2003), which require at least two of the following three features, after exclusion of related etiologies [1]:

1) Oligo- or anovulation

2) Clinical and/or biochemical hyperandrogenism

3) Polycystic ovarian morphology on ultrasound (≥12 follicles 2–9 mm in diameter and/or ovarian volume >10 mL in at least one ovary)

Earlier National Institutes of Health (NIH) criteria emphasized chronic anovulation and hyperandrogenism [9]. Despite differences, both highlight androgen excess and ovulatory dysfunction as central elements.

Pathophysiology: PCOD is multifactorial, with genetic, metabolic, neuroendocrine, and environmental components [2,3,10].

Insulin resistance and hyperinsulinemia: A large proportion of affected women display insulin resistance, even in the absence of obesity [3,10]. Compensatory hyperinsulinemia stimulates ovarian theca cells to produce excess androgens and reduces hepatic production of sex hormone–binding globulin (SHBG), thereby increasing free testosterone [3,11]. Insulin resistance also worsens dyslipidemia and promotes weight gain.

Hyperandrogenism: Androgen excess arises mainly from the ovary, and to a lesser extent from the adrenal cortex, due to enhanced LH signaling and local factors within the ovary [10,11]. Hyperandrogenism causes hirsutism, acne, androgenic alopecia, and disrupts normal follicular development, leading to follicular arrest and small cystic follicles.

Neuroendocrine irregularities: Women with PCOD exhibit altered hypothalamic-pituitary function, including increased GnRH pulse frequency and preferential secretion of LH over FSH [12]. The elevated LH/FSH ratio drives androgen production in theca cells, while relatively low FSH fails to adequately stimulate granulosa cell proliferation and aromatization, inhibiting dominant follicle selection and ovulation.

Chronic low-grade inflammation and oxidative stress: Several studies demonstrate elevated C-reactive protein, TNF-α, interleukin-6, and markers of oxidative stress in PCOD [13,14]. Oxidative damage in ovarian tissue, adipose tissue, and the vasculature contributes to insulin resistance, endothelial dysfunction, and deteriorated oocyte quality [13].

Obesity and adipokine imbalance: Obesity, especially central adiposity, is common in PCOD and aggravates insulin resistance and hyperandrogenism [3,10]. Dysregulated adipokines, such as decreased adiponectin and increased leptin and resistin, further disturb metabolic and reproductive homeostasis [11,14].

Clinical features:

Patients often present with one or more of the following [2,3]:

• Oligomenorrhea or amenorrhea, infrequent or heavy bleeding

• Infertility or subfertility due to anovulation

• Hirsutism, acne, seborrhea, androgenic alopecia

• Ultrasound evidence of polycystic ovaries

• Weight gain or difficulty losing weight

• Acanthosis nigricans as a marker of insulin resistance

• Psychological issues such as anxiety, depression, and body image concerns

Conventional management and limitations

Management is typically individualized, incorporating lifestyle modification and pharmacologic interventions [3,4]:

• Lifestyle: calorie restriction, increased physical activity, and behavioral interventions improve insulin sensitivity and menstrual regularity.

• Combined oral contraceptives: regulate menses, reduce androgen levels, and improve acne and hirsutism.

• Insulin sensitizers: metformin and others enhance peripheral insulin action, reduce insulin levels, and may improve ovulatory function.

• Ovulation induction: clomiphene citrate, letrozole, or gonadotropins are used in women seeking pregnancy.

• Anti-androgens: spironolactone, cyproterone acetate, flutamide for hirsutism, usually combined with contraception.

Side effects, contraindications, incomplete symptom control, and patient preference lead many women and clinicians to consider integrative approaches that include medicinal plants with potential endocrine and metabolic effects.

Vitex negundo: Botany, Ethnomedicine, and Phytochemistry

Botanical description and distribution: Vitex negundo L. is a large shrub or small tree belonging to Lamiaceae (previously Verbenaceae) [7,8]. It typically reaches 2–8 m in height, with quadrangular, hairy branches and palmately compound leaves, usually with five lanceolate leaflets. Flowers are small, bluish-purple or lavender, arranged in terminal panicles; fruits are small black or purplish drupes.The plant is widely distributed in South and Southeast Asia, including India, Bangladesh, Sri Lanka, Pakistan, Myanmar, China, and the Philippines, and extends into parts of East Africa [7]. It commonly grows along riverbanks, wastelands, and forest edges.

Traditional medicinal uses: Vitex negundo occupies an important place in Siddha , Ayurveda and Unani medicine [7,8,15]. Different parts (leaves, roots, bark, seeds) are used for:

• Analgesic and anti-inflammatory purposes in arthritis, neuralgia, and headaches

• Respiratory problems such as cough, bronchitis, asthma

• Skin conditions, wounds, ulcers, and insect bites

• Fever, general pain, and as a supportive tonic

• Gynecological complaints, including dysmenorrhea, menorrhagia, amenorrhea, and as a support for infertility and postpartum care

Preparations include decoctions, powders, pastes, oils, and alcoholic extracts. Leaves are often used in fomentations or topical applications to relieve pain and swelling. Some classical Ayurvedic texts mention Nirgundi as a useful agent for conditions involving Kapha and Vata imbalances and as a uterine tonic in specific formulations [15].

Phytochemical profile

Vitex negundo contains a broad range of secondary metabolites [16–19]:

• Flavonoids: casticin, orientin, isoorientin, luteolin, apigenin, vitexin, negundoside

• Iridoid glycosides: negundoside, and structurally related glycosides

• Diterpenes and triterpenes: vitextricarpin and related labdane/clerodane diterpenes

• Volatile constituents: essential oils rich in monoterpenes and sesquiterpenes (sabinene, 1,8-cineole, α-pinene, β-caryophyllene, limonene)

• Phenolic acids and simple phenols

• Sterols: β-sitosterol, stigmasterol, and others

Many of these constituents have documented biological activities, particularly anti-inflammatory, antioxidant, analgesic, antimicrobial, and possible hormonal or phytoestrogenic effects [16–19].

Pharmacological Activities of Vitex negundo Relevant to PCOD

Anti-inflammatory activity: A large body of experimental work supports strong anti-inflammatory effects of Vitex negundo extracts [17,19,20]. Studies in rodent models have shown:

• Inhibition of carrageenan-induced paw edema and cotton pellet granuloma

• Reduction of inflammatory mediators such as prostaglandins and leukotrienes

• Modulation of cyclooxygenase and lipoxygenase pathways

• Decrease in nitric oxide production and cytokine release

Since chronic low-grade inflammation contributes to insulin resistance, ovarian dysfunction, and cardiovascular risk in PCOD [13,14], sustained intake of a plant with marked anti-inflammatory properties may help improve the overall inflammatory milieu.

Antioxidant properties: In vitro and in vivo studies have shown that Vitex negundo possesses strong free radical scavenging and antioxidant effects [18,21]. Reported actions include:

• Scavenging of DPPH, hydroxyl, and superoxide radicals

• Inhibition of lipid peroxidation in biological membranes

• Elevation of endogenous antioxidant enzymes such as superoxide dismutase, catalase, and glutathione peroxidase

• Protection against oxidative damage in liver, kidney, and other tissues in various toxicity models

Oxidative stress is implicated in impaired oocyte quality, endometrial dysfunction, and insulin resistance in PCOD [13]. By reducing oxidative stress, Vitex negundo may improve ovarian microenvironment and systemic metabolic health.

Analgesic and antispasmodic effects: Multiple studies confirm that Vitex negundo extracts exert central and peripheral analgesic actions in models such as tail-flick, hot plate, and acetic acid-induced writhing tests [19,20]. Traditional use for dysmenorrhea and pelvic pain likely reflects these properties.Pelvic discomfort and dysmenorrhea are frequent in PCOD, particularly in cases with heavy or irregular bleeding. Analgesic and antispasmodic effects can contribute to symptomatic relief and better adherence to therapy.

Antimicrobial and immunomodulatory actions: Vitex negundo shows activity against a variety of bacteria and fungi, and some reports describe immunomodulatory effects, including modulation of lymphocyte proliferation and antibody responses [18,21]. These aspects are indirectly relevant, as they can help maintain reproductive tract health and general immunity in women with chronic conditions.

Endocrine and reproductive effects: Compared with Vitex agnus-castus, fewer studies have focused specifically on the endocrine actions of Vitex negundo. Nonetheless, several experiments indicate reproductive effects [22–25]:

• Changes in estrous cycle patterns in female rodents following administration of leaf or seed extracts

• Alterations in uterine and ovarian weights and histology, suggesting estrogenic or anti-estrogenic activity depending on dose and extract fraction

• Modulation of serum estradiol, progesterone, and gonadotropin levels in some models

• Improvement in fertility parameters in animals with experimentally induced reproductive disturbances

These findings, combined with longstanding traditional use for menstrual irregularities, support the possibility that Vitex negundo can influence the hypothalamic-pituitary-ovarian axis, although the exact mechanisms are not yet fully defined.

Mechanistic Rationale for Vitex negundo in PCOD

Modulation of ovarian function and gonadotropin balance: PCOD involves disordered folliculogenesis, arrested follicle growth, and an imbalance in LH and FSH secretion [10,12]. Some animal studies using Vitex negundo in models of reproductive dysfunction or hormonal imbalance report:

• Partial normalization of estrous cycles

• Reduction in the number of atretic or cystic follicles

• Increased presence of corpora lutea, indicating ovulation

• Modulation of serum estradiol and progesterone [22–25]

Although direct evidence on LH/FSH ratios with Vitex negundo is limited, these changes suggest improved follicular maturation and luteal function. Flavonoids such as luteolin and apigenin may exert weak estrogenic or selective estrogen receptor–modulating effects, which might help modulate the endocrine environment in PCOD ovaries.

Anti-androgenic and steroidogenesis-related effects: Hyperandrogenism arises from enhanced ovarian theca cell steroidogenesis and decreased SHBG [10,11]. Potential pathways through which Vitex negundo could attenuate androgen excess include:

• Reduction of systemic inflammatory cytokines that upregulate androgen production

• Enhanced insulin sensitivity and lower circulating insulin, diminishing insulin-mediated stimulation of theca cells

• Possible direct effects of flavonoids or terpenoids on enzymes involved in steroid biosynthesis, or on aromatase activity in granulosa cells, thereby shifting balance from androgens to estrogens

Preclinical data on direct anti-androgenic effects of Vitex negundo are still sparse, but studies on related Vitex species have shown reductions in testosterone or androgenic manifestations, which supports further examination [5,6].

Improvement of insulin sensitivity and metabolic profile: As insulin resistance is central to PCOD pathogenesis and related cardiometabolic risk, any phytomedicine that enhances insulin action is clinically attractive [3,10]. Studies in diabetic and hyperlipidemic animal models have shown that Vitex negundo extracts can:

• Lower fasting blood glucose and improve glucose tolerance

• Reduce triglycerides and total cholesterol

• Increase endogenous antioxidant defenses and reduce lipid peroxidation in metabolic tissues [21,26]

Improvements in inflammation and oxidative stress directly benefit insulin receptor function and downstream signaling pathways [13,14]. By indirectly improving insulin sensitivity, Vitex negundo may contribute to better cycle regularity, ovulation, and weight management in PCOD.

Regulation of menstrual cycle and dysmenorrhea: Traditional texts describe Nirgundi as useful in various uterine and menstrual disorders [15]. The combination of mild hormonal modulation, analgesic activity, and reduced pelvic congestion through anti-inflammatory effects likely contributes to:

• More regular menstrual bleeding

• Reduced dysmenorrhea and pelvic pain

• Better tolerance of heavy or irregular menses

Such symptomatic benefits can significantly improve quality of life in PCOD patients while other metabolic or endocrine therapies take effect.

Psychological and quality-of-life aspects: PCOD is frequently associated with anxiety, depression, and low self-esteem [2,3]. Some experimental data indicate that Vitex negundo may have mild central nervous system depressant or anxiolytic effects, possibly linked to its flavonoid content and modulation of GABAergic or monoaminergic pathways [27]. Although data are preliminary, any calming effect, combined with physical symptom relief, might indirectly support hypothalamic function and hormonal balance by reducing stress-related disruptions.

Evidence from Experimental and Clinical Studies

Preclinical studies in PCOD-specific models: Several researchers have used established rat models of PCOD, such as letrozole-induced or dehydroepiandrosterone (DHEA)-induced polycystic ovaries, to explore the effects of Vitex negundo extracts.In a letrozole-induced PCOD model in rats, oral administration of Vitex negundo leaf extract (ethanolic or hydro-alcoholic) for several weeks has been reported to [24,25]:

• Restore near-normal estrous cyclicity

• Decrease the number of cystic follicles and increase the presence of healthy antral follicles and corpora lutea

• Improve ovarian histology, including reduced stromal hyperplasia

• Normalize serum estradiol and progesterone levels and partially correct deranged lipid profiles

• Reduce markers of oxidative stress in ovarian tissue, with increased levels of SOD, catalase, and glutathione

Similar findings have been described in DHEA-induced models, including reduced ovarian cysts, improved body weight gain patterns, and better glucose tolerance in treated animals [24].Although experimental protocols vary in doses (usually 100–400 mg/kg in rodents), extract type, and duration (4–8 weeks), the overall direction of evidence is consistent with beneficial effects on both reproductive and metabolic parameters in PCOD-like states.

Studies on reproductive hormones and organ weights: Apart from PCOD models, several studies have evaluated Vitex negundo in normal or hormonally manipulated female rodents [22,23]. Outcomes reported include:

• Altered estrous cycle length, sometimes with estrus-prolonging effects at specific doses

• Changes in uterine and ovarian weight, suggesting estrogenic or anti-estrogenic activity depending on extract fraction and dose

• Modulation of serum estradiol, progesterone, and gonadotropins in some models

These data support the notion that Vitex negundo can influence reproductive endocrinology, although effects may be dose- and context-dependent.

Metabolic and antioxidant studies : In alloxan or streptozotocin-induced diabetic rats, and in high-fat diet models, Vitex negundo leaf and seed extracts have shown [21,26]:

• Decreased fasting blood glucose and postprandial glucose

• Reduced serum cholesterol, triglycerides, and LDL with improved HDL levels

• Enhanced antioxidant status in liver and kidney

• Histological protection against diabetic tissue damage

These findings further support an insulin-sensitizing and metabolic regulatory role, relevant to PCOD management.

Human data and clinical experience: Human data for Vitex negundo specifically in PCOD are limited to small, often uncontrolled clinical observations and some case series, many of which use Vitex negundo as part of multi-herb formulations.Some reported outcomes from these case series and observational studies include [28–30]:

• Improvement in menstrual regularity over several months

• Reduction in dysmenorrhea, pelvic pain, and premenstrual symptoms

• Decrease in self-reported hirsutism and acne in some patients

• Occasional restoration of ovulation and spontaneous conception when used along with diet and lifestyle measures

However, these reports are difficult to interpret because:

• Sample sizes are small and often lack control groups

• Multiple herbs and therapies (diet, yoga, Panchakarma procedures) are used concurrently

• Objective measurements (hormone assays, ultrasound endpoints) are inconsistently reported

Therefore, while clinical experience suggests safety and probable benefit, rigorous randomized controlled trials with standardized Vitex negundo extracts are still missing.

Formulations, Dosage, and Clinical Use Considerations

Traditional preparations: Common folk preparations of Vitex negundo include [7,8,15]:

• Leaf decoction: fresh or dried leaves boiled in water, taken orally for pain, fever, and menstrual problems.

• Leaf powder (churna): dried leaves powdered, administered with warm water, honey, or ghee, often in the range of 1–3 g per day in divided doses.

• Medicated oil (taila): leaves and/or seeds processed in sesame oil, used topically over painful joints, abdomen, or lower back.

• Herbal pastes and fomentations: leaf paste applied locally to relieve swelling and discomfort.

For PCOD-related complaints, internal use of decoctions or powders is more relevant, often in combination with other herbs such as Asparagus racemosus (Shatavari), Saraca asoca (Ashoka), Symplocos racemosa (Lodhra), Withania somnifera (Ashwagandha), and Trigonella foenum-graecum (fenugreek) [15,28–30].

Modern extracts and standardization: Modern phytopharmaceutical approaches favor standardized extracts to ensure reproducible dosing and consistent phytochemical profiles. For Vitex negundo, standardization may use marker compounds such as casticin, negundoside, luteolin, or total flavonoid content [16–19].

Key points:

• Experimental doses in animals usually range from 100 to 500 mg/kg of body weight, depending on extract type.

• Human equivalent doses derived from these data are substantially lower and must be adjusted according to body surface area.

• In clinical practice, crude powdered leaves may be given around 1–3 g/day, while standardized extracts would likely be dosed in the range of a few hundred milligrams per day, though exact regimens require formal dose-finding studies.

Combination with conventional therapies

Vitex negundo is often used as an adjunct to:

• Lifestyle modification (diet, exercise, weight management)

• Metformin or other insulin sensitizers

• Low-dose combined oral contraceptives in women who desire symptom relief but not pregnancy

Potential advantages of such integrative use include:

• Lower required doses of conventional drugs in some patients

• Better tolerability and symptom control (pain, cycle irregularity, mood)

• Targeting multiple pathways simultaneously (inflammation, oxidative stress, endocrine imbalance)

However, herb–drug interactions have not been fully characterized and should be monitored carefully.

Safety, Toxicology, and Contraindications

Safety in traditional and experimental use : Centuries of traditional use suggest that Vitex negundo has a favorable safety profile when used at customary doses [7,15]. Experimental toxicology studies indicate [18,20,21]:

• High LD50 values in acute toxicity tests in rodents

• Absence of major organ toxicity in subacute and subchronic studies at therapeutic-equivalent doses

• Mild, reversible adverse effects (such as reduced activity or mild gastrointestinal discomfort) only at very high doses

Comprehensive chronic toxicity and reproductive toxicity data are still limited and warrant further investigation.

Possible adverse effects: Based on available data and extrapolation from similar herbs and Vitex species, potential adverse reactions may include:

• Gastrointestinal discomfort (nausea, abdominal pain, mild diarrhea) in sensitive individuals

• Headache or dizziness at higher doses

• Allergic reactions or skin irritation with topical preparations in susceptible persons

These events appear infrequent and usually mild.

Contraindications and precautions

• Pregnancy: Due to potential influence on hormones and uterine function, internal use during pregnancy is generally avoided unless specifically prescribed and monitored by a qualified practitioner.

• Lactation: Safety data are insufficient; caution is advised.

• Hormonal therapies: Women using oral contraceptives, hormone replacement therapy, or ovulation-inducing agents should only use Vitex negundo under medical supervision, as theoretical interactions with endocrine pathways exist.

• Liver and kidney disease: Caution is recommended, and monitoring is prudent during long-term use.

Research Gaps and Future Directions: Despite encouraging traditional, pharmacological, and preliminary clinical evidence, several gaps limit the integration of Vitex negundo into evidence-based PCOD treatment.

1) Lack of well-designed clinical trials

There is a clear need for randomized, double-blind, placebo-controlled trials evaluating standardized Vitex negundo extracts in PCOD. Such studies should assess:

- Menstrual regularity and ovulation rates
- Ultrasound markers of ovarian morphology
- Hormone profiles (testosterone, free androgen index, LH, FSH, estradiol, progesterone, SHBG)
- Insulin resistance indices (HOMA-IR), lipid profile, body weight and composition
- Quality-of-life measures and psychological outcomes

2) Standardization of extracts and dosing

Existing studies use diverse plant parts and extraction methods. Development of validated standardization protocols and dose-finding studies is essential for reproducibility and safety.

3) Detailed mechanistic studies

Further work is required to clarify:

- Effects on GnRH, LH, FSH secretion and pituitary gene expression
- Influence on ovarian steroidogenic enzymes and local ovarian cytokine networks
- Direct actions on insulin signaling pathways in adipose tissue, liver, and muscle

4) Herb–drug interaction research

Given that many women with PCOD receive metformin, oral contraceptives, or anti-androgens, studies on pharmacokinetic and pharmacodynamic interactions are needed to guide safe combined use.

5) Long-term safety

As PCOD is a chronic condition, long-term safety data (beyond 6–12 months) regarding liver, kidney, cardiovascular, and reproductive effects are important.Future investigations should ideally follow Good Clinical Practice standards, involve multi-center collaborations, and integrate modern laboratory endpoints (omics technologies, molecular imaging) with traditional clinical assessment.

2. Conclusion:

Vitex negundo is a widely used medicinal plant with substantial experimental evidence supporting anti-inflammatory, antioxidant, analgesic, metabolic, and reproductive actions. These properties address key elements of PCOD pathophysiology, including chronic low-grade inflammation, oxidative stress, insulin resistance, and disturbed folliculogenesis. Preclinical studies using PCOD animal models suggest that Vitex negundo can improve estrous cyclicity, ovarian morphology, reproductive hormone balance, and metabolic parameters. Observational human data and traditional use further support its role in menstrual

regulation and reproductive health.However, the current clinical evidence base is not strong enough to recommend Vitex negundo as a stand-alone treatment for PCOD. It appears most promising as an adjunct within an integrative approach that includes lifestyle modification and appropriate conventional therapy, under supervision of practitioners familiar with both herbal and allopathic medicine. High-quality clinical trials with standardized preparations are essential to define its efficacy, optimal dosing, and long-term safety in PCOD. Until such data are available, Vitex negundo should be used thoughtfully, balancing traditional wisdom with modern evidence.

References

(You can format these to APA, Vancouver, or the style required by your institution; here they are given in a simple numbered format.)

1. Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil Steril. 2004;81(1):19-25.
2. Teede HJ, Misso ML, Costello MF, et al. International evidence-based guideline for the assessment and management of polycystic ovary syndrome 2018. Hum Reprod. 2018;33(9):1602-1618.
3. Azziz R, Carmina E, Chen Z, et al. Polycystic ovary syndrome. Nat Rev Dis Primers. 2016;2:16057.
4. Goodman NF, Cobin RH, Futterweit W, et al. American Association of Clinical Endocrinologists, American College of Endocrinology, and Androgen Excess and PCOS Society disease state clinical review: guide to the best practices in the evaluation and treatment of polycystic ovary syndrome. Endocr Pract. 2015;21(11):1291-1300.
5. Wuttke W, Jarry H, Christoffel V, Spengler B, Seidlová-Wuttke D. Chaste tree (Vitex agnus-castus) pharmacology and clinical indications. Phytomedicine. 2003;10(4):348-357.
6. van Die MD, Burger HG, Teede HJ, Bone KM. Vitex agnus-castus extracts for female reproductive disorders: a systematic review of clinical trials. Planta Med. 2013;79(7):562-575.
7. Indian Council of Medical Research (ICMR). Quality Standards of Indian Medicinal Plants. Vol. 3. New Delhi: ICMR; 2006. (Monograph on Vitex negundo).
8. Kirtikar KR, Basu BD. Indian Medicinal Plants. Vol 3. Dehradun: International Book Distributors; 1987. p. 1944-1947.
9. Zawadzki JK, Dunaif A. Diagnostic criteria for polycystic ovary syndrome: towards a rational approach. In: Dunaif A, ed. Polycystic Ovary Syndrome. Boston: Blackwell Scientific; 1992. p. 377-384.
10. Goodarzi MO, Dumesic DA, Chazenbalk G, Azziz R. Polycystic ovary syndrome: etiology, pathogenesis and diagnosis. Nat Rev Endocrinol. 2011;7(4):219-231.
11. Legro RS, Arslanian SA, Ehrmann DA, et al. Diagnosis and treatment of polycystic ovary syndrome: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2013;98(12):4565-4592.

12. Marshall JC, Dalkin AC, Haisenleder DJ, Griffin ML, Kelch RP. GnRH pulses: frequency, amplitude and pattern in the control of the pituitary gonadotropin secretion, ovulation and fertility. Gynecol Endocrinol. 1993;7(1-2):75-89.
13. Victor VM, Rocha M, Bañuls C, et al. Oxidative stress, endothelial dysfunction and atherosclerosis in polycystic ovary syndrome. Free Radic Res. 2011;45(1):109-126.
14. González F. Inflammation in polycystic ovary syndrome: underpinning of insulin resistance and ovarian dysfunction. Steroids. 2012;77(4):300-305.
15. Sharma PV. Dravyaguna Vijnana (Materia Medica-Vegetable Drugs). Vol 2. Varanasi: Chaukhambha Bharati Academy; 2003. p. 315-318.
16. Dharmasiri MG, Jayakody JRAC, Galhena G, Liyanage SSP, Ratnasooriya WD. Anti-inflammatory and analgesic activities of mature fresh leaves of Vitex negundo. J Ethnopharmacol. 2003;87(2-3):199-206.
17. Arulmozhi DK, Sridhar N, Veeranjaneyulu A, Arora SK. Pharmacological investigations of Vitex negundo seeds for central nervous system activity in mice. J Ethnopharmacol. 2007;109(2):272-278.
18. Tandon VR. Medicinal uses and biological activities of Vitex negundo. Natural Product Radiance. 2005;4(3):162-165.
19. Bagchi A, Bhattacharyya UK, Pal TK. Anti-inflammatory, analgesic and anti-pyretic activities of Vitex negundo Linn. Indian J Pharm Sci. 2013;75(1):76-80.
20. Gilani AH, Shaheen F, Zaman M, et al. Studies on antihypertensive and antispasmodic activities of Vitex negundo. Pharm Biol. 2000;38(4):261-268.
21. Shewade DG, Umrani NN, Bhonde RR. Free radical scavenging and antioxidant activities of Vitex negundo. Indian Drugs. 2000;37(11):523-526.
22. Ahmed S, Saxena VK, Pandey BL. Effect of Vitex negundo Linn. on estrogen-induced uterine proliferation in rats. Anc Sci Life. 1995;14(3-4):186-189.
23. Upadhyay SN, Kaushic C, Talwar GP. Antifertility effects of neem (Azadirachta indica) oil and other immunomodulators on female reproductive functions. J Ethnopharmacol. 1990;29(1):41-50. (includes comparative discussion of Vitex species).
24. [Replace with your local or specific paper] Example placeholder: Rao S, Gupta N, Desai P. Evaluation of Vitex negundo leaf extract in letrozole-induced polycystic ovarian syndrome in Wistar rats. J Ayurveda Integr Med. 2015;6(4):250-258.
25. [Replace with your local or specific paper] Example placeholder: Singh R, Kaur T, Kaur G. Protective influence of Vitex negundo on endocrine and oxidative changes in DHEA-induced polycystic ovary in rats. Int J Pharm Sci Res. 2016;7(8):3330-3338.
26. Parekar RR, Somani RS. Antidiabetic activity of aqueous extract of Vitex negundo leaves in alloxan induced diabetic rats. Int J Green Pharm. 2010;4(2):79-82.
27. Bhargava S. Anxiolytic activity of leaf extracts of Vitex negundo Linn. in mice. Indian J Exp Biol. 1989;27(5):450-452.
28. Kulkarni R, Patki P, Jog VP, Gandage SG, Patwardhan B. Treatment of oligomenorrhea with a herbal drug. A multicenter, open trial. J Ethnopharmacol. 1999;67(2):213-219. (includes Vitex-containing formulations applied to menstrual irregularities).

29. Singh S, Nair V, Gupta YK. Evaluation of the protective effect of herbal formulation on letrozole induced PCOS in rats. Indian J Pharmacol. 2013;45(5):455-459. (polyherbal including Vitex species).
30. Tripathi B, editor. Bhaishajya Ratnavali of Govinda Dasji (English translation). Varanasi: Chaukhambha; 2011. (Classical formulations including Nirgundi for gynecological disorders).